Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients with Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

NCT04145297 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT04145297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04145297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients with Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Completed
Start date
March 17, 2020
Completion date
August 18, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasms